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Abstract 
 
Background. It has been suggested that albuminuria is useful in identifying persons at increased risk of coronary 
heart disease (CHD). Australian Aborigines have exceedingly high rates of renal failure together with increased CHD 
mortality. We undertook this prospective cohort study to assess the independent effect of albuminuria on CHD risk in 
Aboriginal people in the Northern Territory of Australia. 
Methods. We examined the relation between micro- and macroalbuminuria and incident CHD in a sample of 870 
Aboriginal adults aged 20 to74 years old without prevalent baseline CHD. Cox proportional hazards models were used 
to assess the association between baseline albuminuria and CHD incidence. 
Results. During a median of 9.2 years of follow-up, 89 CHD events occurred during the follow-up period (1992 to 
2003). The incidence of CHD increased significantly across categories of albuminuria (4.4, 10.9, and 29.8 per 1000 
person-years for normoalbuminuria, microalbuminuria, and macroalbuminuria, respectively). The multiple Cox 
proportional hazards regression showed the hazard ratio was 3.4 (95% CI 1.6, 7.3), adjusting for age, gender, body 
mass index (BMI), blood pressure, total cholesterol, diabetes status, cigarette smoking, and alcohol consumption, for 
macroalbuminuria group. Hazard ratio for microalbuminuria group was not significantly different from unity during 
the first 6 years of follow-up but significantly higher during the follow-up period >6 years with adjusted hazard ratio 9.0 
( 9 5 %  CI 2.0, 40.0). 
Conclusion. Independent of traditional cardiovascular risk factors, both microalbuminuria and macroalbuminuria 
may be useful in identifying persons at increased risk of CHD in Aboriginal people. 
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Aboriginal Australians have a high rate of end-stage of renal disease (ESRD) together with increased 
cardio-vascular mortality [1]. They also have higher prevalence of albuminuria than Australians of 
European descent [2]. An association between albuminuria and subsequent cardiovascular mortality in 
Aboriginal people was demonstrated [3]. Cross-sectional studies showed a powerful association between 
albuminuria and cardiovascular risk factors [4–6]. It has been found in non-Aboriginal populations that 
any degree of albuminuria is a risk factor for cardiovascular events in diabetic and nondiabetic individuals 
[7]. Microalbuminuria is useful in identifying persons at increased risk of coronary heart disease (CHD) in 
the general British population [8]. 
Although the significance of albuminuria as a possible predictor of CHD has been suggested [6, 9], 
there has not been a cohort study of albuminuria and incident CHD in Aboriginal people. It is not clear if 
the association between albuminuria and CHD risk is independent of the traditional risk factors this 
population. Therefore, we undertook this prospective study, with a median of 9.2 years of follow-up, to 
examine the relationship between albuminuria levels and future CHD events. 
 
METHODS 
From 1992 to 1995, a community-wide renal disease screening program, involving 897 adults aged 20 
to 74 years old, was conducted in a remote island community in Northern Territory. There were 878 
who had a baseline measurement of urine albumin/creatinine ratio. Eight participants were excluded 
because their hospital records showed preexisting CHD events. Thus, 870 people representing over 80% 
the adult population in the community were included in this study. 
Measurements 
The urinary albumin and creatinine concentrations were measured on a random urine specimen. Urinary 
albumin concentration was measured by the Beckman immunoassay (Beckman Instruments, Fullerton, 
CA, USA). An albumin:creatinine ratio (ACR) was calculated (mg/mmol). Previous studies in Aboriginal 
people used 3.4 mg/mmol and 34 mg/mmol as cutoffs for micro-and macro- (or overt) albuminuria [3–6]. 
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Other studies defined microalbuminuria as an ACR of 2.0 mg/mmol [7]. However, to be consistent with 
recent cohort studies on predictive values of albuminuria on heart disease, this study defined 
normoalbuminuria as an ACR less than 2.5 mg/mmol, microalbuminuria as an ACR 2.5 to 25 mg/mmol, 
and macroalbuminuria as an ACR greater than 25 mg/mmol [8, 10, 11]. CHD risk factors such as blood 
pressures, serum cholesterol, triglycerides, body mass index (BMI), cigarette smoking, alcohol drinking, 
and the presence of diabetes were described elsewhere [12–14].  
 
CHD 
We identified fatal and nonfatal CHD events occurring between baseline and follow-up through 
December 31, 2003. CHD events were defined from hospital and death records using the codes of 
Internationl Classification of Diseases, Ninth edition (ICD-9-CM) codes 410–414 and ICD-10-AM codes 
I20-I25. Hospital Registration Numbers were used to link CHD events with baseline data. 
 
Table 1. Baseline characteristics of study participants by categories of albuminuria 
 
        Albumin:creatinine ratio (ACR) category 
             Normoalbuminuria        Microalbuminuria    Macroalbuminuria 
             0.00–2.49 mg/mmol      2.50–25.0 mg/mmol  >25 mg/mmol              P value 
Number (%) 389 (45) 265 (30) 216 (25)  
Age years 30.3 (10.2) 34.5 (11.8) 41.6 (12.3) <0.001 
Body mass index kg/m2a 22.3 (4.7) 24.4 (5.2) 26.1 (5.7) <0.001 
Total cholesterol mmol/L a 4.4 (1.0) 4.7 (1.0) 5.2 (1.3) <0.001 
Systolic pressure mm Hg a 116.5 (16.4) 122.0 (16.5) 130.5 (20.8) <0.001 
Diastolic pressure mm Hg a 70.5 (11.4) 75.2 (13.2) 81.6 (15.2) <0.001 
UrineACR mg/mmol b 0.7 (0.7, 0.8) 7.3 (6.7, 7.9) 84.1 (75.8, 93.3) <0.001 
Triglycerides mmol/L b 1.6 (1.5,1.7) 1.9 (1.8, 2.0) 2.5 (2.3, 2.8) <0.001 
Male (%) 209 (53.7) 142 (53.6) 91 (42.1) 0.0132 
Smoking (%) 294 (75.6) 186 (70.2) 148 (68.5) 0.1223 
Drinking (%) 225 (57.8) 157 (59.2) 109 (50.5) 0.1166 
Diabetes (%) 20 (5.1) 27 (10.2) 71 (32.9) <0.001 
 
a Mean (SD). 
b Geometric mean (95% CI). 
 
Statistical analysis 
CHD incidence rates were calculated by dividing the number of first-ever CHD events by the person-
years of follow-up according to the three categories of albuminuria. Hazard ratios and their 95% CIs 
were estimated using the Cox proportional hazards model, adjusting for potential confounding factors of 
(1) age and gender and (2) age, gender, smoking, alcohol drinking, blood pressure, BMI, serum 
cholesterol, and diabetes status. 
 
Table 2. Pearson correlation coefficients between baseline albumin:creatinine ratio (ACR) and follow-up 
ACRs 
 
Time after baseline Correlation coefficients Number 
ACR year 1 0.8278 306 
ACR year 2 0.7959 220 
ACR year 3 0.7631 280 
ACR year 4 0.7392 213 
ACR year 5+ 0.6412 146 
 
In a subset of study sample, 598 participants had at least one subsequent urine ACR measurements 
from 1 to 5 years after the initial measurement. To understand how well the baseline ACR measurement 
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can reflect the usual ACR level during the follow-up period, correlation coefficients between initial 
measurement and subsequent measurements were calculated. All analyses were performed using Stata 
version 8 [15]. 
 
Ethics approval 
The project was approved by the Behavioural and Social Science Ethical Review Committee of the 
University of Queensland, the Human Research Ethics Committee of the Northern Territory Department 
of Health and Community Services and Menzies School of Health Research, and the community health 
board. 
 
RESULTS 
 
Baseline characteristics 
Thirty percent of participants had microalbuminuria and 25% had macroalbuminuria. Table 1 shows 
baseline characteristics of the study population by categories of albuminuria. Albuminuria was 
significantly associated with a number of cardiovascular risk factors, including age, blood pressure, total 
cholesterol, BMI, triglycerides, and diabetes. 
 
Correlations between baseline and subsequent measurements 
Based on a convenient sample, the baseline ACR measurement was significantly correlated with follow-
up ACR measurements. The correlation decreased with the duration of follow-up from 0.83 at year 1 to 
0.64 at year 5 after the baseline measurement (Table 2). 
 
Table 3. Incidence of coronary heart disease (CHD) by categories of albuminuria in Aboriginal people 
 
Albuminuria CHD events Person-years Incidence (95% CI)/ 1000 person-years 
Normal 15  3426.7 4.4 (2.6, 7.3) 
Micro 25  2297.6 10.9 (7.4, 16.1) 
Macro 49  1645.1 30.0 (22.5, 39.4) 
 
 
 
 
Fig. 1.  Albuminuria and coronary heart disease (CHD) incidence in Aboriginal Australians. 
 
Association between albuminuria and CHD 
A total of 89 CHD events occurred during a median of 9.2 years in 870 participants. Fifty one (57%) 
participants had acute myocardial infarction and 26 (29%) had angina pectoris. As is shown in Table 3 and 
Figure 1, the incidence of CHD increased significantly across categories of base-line albuminuria. After 
adjusting for age and gender with normoalbuminuria as the reference group, the CHD risk was about 
doubled for microalbuminuria and about four-fold for macroalbuminuria during the whole follow-up 
period (Table 4). The increased CHD risk for microalbuminuria and macroalbuminuria groups remained 
after adjustment for major CHD risk factors including age, gender, BMI, blood pressure, total 
cholesterol, diabetes status, cigarette smoking, and alcohol consumption. The risk of CHD for 
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microalbuminuria group increased dramatically after 6 years. We divided the follow-up time into two 
periods: <6 years and >_6 years. The interaction term between follow-up time and microalbuminuria was 
found to be statistically significant. Therefore, the hazard ratios for two time periods are presented in 
Table 4. The hazard ratio 0.96 (0.34, 2.7) for microalbuminuria group was not significantly different from 
unity during early follow-up period although it was significantly higher during the period >6 years (Table 
4). 
 
Table 4. Hazard ratios (95% CI) for coronary heart disease (CHD) by categories of albuminuria in 
Aboriginal people 
              Overall follow-up period               Follow-up time <6 years            Follow-up time ≥6 years 
Albuminuria HRa HRb HRa HRb HRa HRb 
Normal 1 1 1 1 1 1 
Micro 2.0 (1.04, 3.8) 2.6 (1.2, 5.5) 0.68 (0.27, 1.7) 0.96 (0.34 2.7) 7.3 (2.1, 25.2) 9.0 (2.0, 40.0) 
Macro 3.9 (2.1, 7.2) 3.4 (1.6, 7.3) 3.5 (1.8, 7.0) 2.9 (1.2, 7.0) 5.1 (1.4, 18.8) 4.9 (1.0, 24.8) 
 
Body mass index, blood pressure, and total cholesterol  were continuous variables. Diabetes status, cigarette 
smoking and alcohol consumption were dichotomous. 
a Adjusting for age and gender. 
b Adjusting for age, gender, body mass index, blood pressure, total cholesterol, diabetes status, cigarette smoking, 
and alcohol consumption.  
 
DISCUSSION 
A growing number of epidemiologic studies have re-ported that microalbuminuria is a strong risk factor 
ofcardiovascular disease [7, 8, 16–20]. This study confirmed that the incidence of CHD increased 
significantly across categories of baseline albuminuria in Aboriginal people. Microalbuminuria and 
macroalbuminuria were in-dependently associated with an increased risk of CHD in comparison with 
normoalbuminuria. Therefore, microalbuminuria and macroabuminuria may be useful indicators, in 
addition to conventional risk factors such as age gender, smoking, total cholesterol, blood pressure, BMI, 
and diabetes, in identifying persons who are at increased risk of primary CHD. 
The data are consistent with previous studies in Aboriginal populations which showed albuminuria 
associated with cardiovascular risk factors [4, 5, 12, 21]. Our prospective data indicate that the contribution 
of albuminuria to CHD risk is independent of traditional risk factors. Microalbuminuria was found to be 
an independent predictor of CHD risk in the general British population in the EPIC-Norfolk Study [8], 
and in a sample from North America, South America and Europe in the Heart Out-comes Prevention 
Evaluation (HOPE) study [7]. 
Our study participants had a higher prevalence of albuminuria than other published data. We found 
30% microalbuminuria and 25% macroalbuminuria in our study sample while in the British population 
there are only 11.6% microalbuminuria and 0.8% macroalbuminuria [8]. An Australian study has shown 
that Aboriginal Australians have a higher prevalence of albuminuria than Australians of European decent 
[2]. However, the association between albuminuria and CHD risk in Aboriginal people in this study is 
consistent with findings in other populations. The age- and gender-adjusted hazard ratio for CHD 
associated with microalbuminuria for the over-all follow-up period is 1.98 (95% CI 1.04, 3.79) in our 
study while the corresponding ratio is 1.65 for British population [8]. The hazards ratio for major 
cardiovascular events associated with microalbuminuria in the HOPE study is 1.83 [7]. Although similar 
relative risks have been found across different populations, microalbuminuria may play a more important 
role in Aboriginal population due to its higher prevalence of microalbuminuria. 
Some limitations of this study should be pointed out. First, the CHD events were identified through 
hospital inpatient and death records. Some minor CHD events not severe enough for hospitalization may 
have been missed. Second, the risk of albuminuria measured on a single occasion at baseline tends to 
underestimate the true association between “usual” albuminuria level and CHD. Regression dilution bias 
is one of concerns for using baseline risk values in cohort studies with a long period of follow-up [22–
24]. The magnitude of regression dilution increases with increasing length of follow-up [24]. The 
correlation coefficients between baseline measurement and resurveyed values have been used to assess the 
magnitude of the bias [24]. The correlation coefficient 
for ACR between baseline and year 5 (r = 0.64) is similar to those for systolic and diastolic blood 
pressures in Framingham and MONICA data [24]. Therefore, the presence of dilution bias tends to 
underestimate the true association between albuminuria and CHD risk. Third, a subset of study 
participants with ACR >34 g/mol or diabetes and ACR >3.4 g/mol received an angiotensinconverting 
Kidney International (2005)  68(3):1289-1293.                               doi:10.1111/j.1523-1755.2005.00525.x 
enzyme (ACE) inhibitor (perindopril) treatment during the follow-up period. [25] Due to the beneficial 
effects of ACE inhibitor and the fact that the treatment mostly occurred in albuminuria groups,[25] the 
incidence of CHD could have been higher in albuminuria groups if the treatment had not been used in this 
population. Therefore, the use of ACE inhibitors among study participants might have diluted the true 
association between albuminuria and CHD. Fourth, although the microalbuminuria group had an 
increased CHD incidence than the normal group during the overall follow-up period, the significant 
difference only appeared after 6 years of follow-up. It remains unanswered if the progression from micro- 
to macroalbuminuria during the follow-up period contributed to this pattern. 
The underlying pathophysiologic mechanism behind the association between albuminuria and CHD is 
still not clear. There are several possible explanations. Albuminuria is a marker of established CHD risk 
factors. There is a large body of data demonstrating associations between microalbuminuria and 
established cardiovascular risk factors, including elevated blood pressure, elevated lipid levels, adiposity, 
carotid intima-media thickness, smoking, and diabetes in both Aboriginal and other populations [4, 5, 12, 
21]. In the present study we observed an association between albuminuria and major risk factors such as 
total cholesterol, blood pressure, and diabetes. However, the association may not be mediated by those 
factors since the association remained after adjustment of those factors. It is suggested that albuminuria 
may reflect endothelial dysfunction that might enhance the penetration of atherogenic lipoproteins into the 
arterial wall [26]. The study of Jensen [27] indicates that atherosclerotic vascular disease is associated 
with renal and systemic transvascular leakiness for albumin, and such leakiness may allow for an increased 
lipid insudation into the large vessel wall, thereby linking microalbumin-uria to atherogenesis. However, 
Agewall and Bjorn [28] suggested microalbuminuria in healthy subjects is not primarily associated with 
atherosclerosis but rather to blood pressure and abdominal obesity. 
Although the true explanation of the pathophysiologic relationship between albuminuria and CHD is 
still not clear, it is important to know that microalbuminuria is a useful independent predictor of CHD 
risk. Improving kidney function may be potentially beneficial to preventing CHD in Aboriginal people. 
Our results suggest that microalbuminuria and macroalbuminuria can be useful for identifying persons 
at increased risk of CHD who might benefit the most from treatment. Conventional risk factors 
underestimated the risk of CHD in Aboriginal people [29]. Albuminuria may be a useful indicator in the 
absolute risk equations in addition to conventional risk factors. 
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